Sure, here is a more detailed paraphrasing of the text:Ozempic, a drug that mimics the body's naturally occurring GLP-1 hormone to make people feel full and eat less, is used to treat diabetes.

A new study has found that patients with opioid use disorder who take a GLP-1 drug like Ozempic have a 40% lower rate of opioid overdose compared to those without a prescription.

Additionally, people with alcohol use disorder reduced their rate of intoxication by half when taking a GLP-1 drug, according to the researchers.

The study authors noted that past research on the effects of GLP-1 drugs on substance abuse has primarily been conducted through animal studies and small-scale clinical trials.

The Post reached out to Danish pharmaceutical giant Novo Nordisk, which manufactures Ozempic and its sister drug, Wegovy, for comment.

The US Food and Drug Administration approved Ozempic in 2017 for treating Type 2 diabetes in adults and Wegovy in 2021 for adult weight loss.

These types of medications interact with the mesolimbic system, a major reward center in the brain that overlaps with the brain processes that govern addictive behaviors.

The researchers suggested that GLP-1 drugs might alter the reward-response pathways linked to substance use.

Christie Martin, a Las Vegas mom and real estate agent, shared last year that she lost her desire to drink after receiving Ozempic injections.

'I have no desire to drink wine anymore,' she shared.

'And that's crazy to me because I couldn't stop before.

'